- Home
- AMWD vs PHAT Comparison
AMWD vs PHAT Comparison
Compare AMWD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMWD
- PHAT
- Stock Information
- Founded
- AMWD 1980
- PHAT 2018
- Country
- AMWD United States
- PHAT United States
- Employees
- AMWD N/A
- PHAT N/A
- Industry
- AMWD Forest Products
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- AMWD Basic Materials
- PHAT Health Care
- Exchange
- AMWD Nasdaq
- PHAT Nasdaq
- Market Cap
- AMWD 760.7M
- PHAT 727.5M
- IPO Year
- AMWD N/A
- PHAT 2019
- Fundamental
- Price
- AMWD $57.00
- PHAT $9.45
- Analyst Decision
- AMWD Buy
- PHAT Strong Buy
- Analyst Count
- AMWD 4
- PHAT 5
- Target Price
- AMWD $83.33
- PHAT $16.40
- AVG Volume (30 Days)
- AMWD 168.3K
- PHAT 1.9M
- Earning Date
- AMWD 08-26-2025
- PHAT 08-07-2025
- Dividend Yield
- AMWD N/A
- PHAT N/A
- EPS Growth
- AMWD N/A
- PHAT N/A
- EPS
- AMWD 6.50
- PHAT N/A
- Revenue
- AMWD $1,709,585,000.00
- PHAT $81,859,000.00
- Revenue This Year
- AMWD N/A
- PHAT $195.45
- Revenue Next Year
- AMWD $4.03
- PHAT $106.76
- P/E Ratio
- AMWD $8.87
- PHAT N/A
- Revenue Growth
- AMWD N/A
- PHAT 3055.70
- 52 Week Low
- AMWD $50.00
- PHAT $2.21
- 52 Week High
- AMWD $106.57
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- AMWD 55.87
- PHAT 60.80
- Support Level
- AMWD $54.43
- PHAT $8.19
- Resistance Level
- AMWD $58.46
- PHAT $9.76
- Average True Range (ATR)
- AMWD 2.18
- PHAT 0.66
- MACD
- AMWD 0.66
- PHAT -0.21
- Stochastic Oscillator
- AMWD 80.79
- PHAT 54.58
About AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.